Table 1 Baseline characteristics of enrolled patients.
From: Prognostic factors and clinical outcomes of stenting on malignant central airway obstruction
Stent group (n = 215) | Non-Stent group (n = 72) | P value | |
|---|---|---|---|
Age (years) | 64.47 ± 13.15 | 66.06 ± 14.46 | 0.156 |
Sex (male, n) | 157 (73.02%) | 55 (76.39%) | 0.574 |
Smoking history, n (%) | 109 (50.70%) | 39 (54.17%) | 0.610 |
Comorbidity, n (%) | 0.589 | ||
Chronic lung disease | 102(47.44%) | 25(34.72%) | |
Chronic liver disease | 35(16.27%) | 12(16.67%) | |
Diabetes | 35(16.27%) | 18(25.00%) | |
Cardiovascular disease | 26(12.09%) | 8(11.11%) | |
Others | 17(7.93%) | 9(12.5%) | |
Final pathological diagnosis | 0.904 | ||
Squamous carcinom | 73(33.95%) | 29(40.25%) | |
Adenocarcinoma | 25(11.63%) | 8(11.11%) | |
SCLC | 6(2.79%) | 2(2.78%) | |
Metastatic malignancy | 111(51.63%) | 33(45.83%) | |
Esophagus cancer | 82(38.13%) | 25(34.72%) | |
Thyroid cancer | 19(8.83%) | 4(5.55%) | |
Others | 10(4.65%) | 4(5.55%) | |
Type of stenosis | 0.584 | ||
Intraluminal type | 6 (2.79%) | 3 (4.17%) | |
Extraluminal type | 66 (30.70%) | 25 (34.72%) | |
Mixed type | 143 (66.51%) | 44 (61.11%) | |
Treatment received before airway stenting | 0.732 | ||
Chemotherapy | 89(41.39%) | 25(34.72%) | |
Radiotherapy | 56(26.05%) | 20(27.77%) | |
Targeted therapy | 43(20.00%) | 18(25.00%) | |
Immunotherapy | 27(12.56%) | 9(12.5%) | |
Stage of tumor | 0.394 | ||
Stage I + II + III | 99 (46.05%) | 29 (40.28%) | |
Stage IV | 116 (53.95%) | 43 (59.72%) | |
Degree of stenosis | 0.617 | ||
Grade II | 30 (13.95%) | 19(26.38%) | |
Grade III | 102(47.44%) | 24(33.33%) | |
Grade IV | 83 (38.60%) | 29(40.29%) | |
Lesion location | 0.001 | ||
Upper trachea | 27 (12.56%) | 0 (0.00%) | |
Lower trachea | 81 (37.67%) | 4 (5.56%) | |
Right primary bronchus | 65 (30.23%) | 12 (16.67%) | |
Left upper bronchus | 13 (6.05%) | 11 (15.28%) | |
Right upper bronchus | 25 (11.63%) | 14 (19.44%) | |
Right middle bronchus | 4 (1.86%) | 31 (43.06%) |
